Michael Heneka to Amyloidogenic Proteins
This is a "connection" page, showing publications Michael Heneka has written about Amyloidogenic Proteins.
Connection Strength
0.297
-
Ferguson CM, Hildebrand S, Godinho BMDC, Buchwald J, Echeverria D, Coles A, Grigorenko A, Vangjeli L, Sousa J, McHugh N, Hassler M, Santarelli F, Heneka MT, Rogaev E, Khvorova A. Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease. Alzheimers Dement. 2024 04; 20(4):2632-2652.
Score: 0.054
-
Heinzinger N, Maass A, Berron D, Yakupov R, Peters O, Fiebach J, Villringer K, Preis L, Priller J, Spruth EJ, Altenstein S, Schneider A, Fliessbach K, Wiltfang J, Bartels C, Jessen F, Maier F, Glanz W, Buerger K, Janowitz D, Perneczky R, Rauchmann BS, Teipel S, Killimann I, G?er? D, Laske C, Munk MH, Spottke A, Roy N, Heneka MT, Brosseron F, Dobisch L, Ewers M, Dechent P, Haynes JD, Scheffler K, Wolfsgruber S, Kleineidam L, Schmid M, Berger M, D?zel E, Ziegler G. Exploring the ATN classification system using brain morphology. Alzheimers Res Ther. 2023 03 13; 15(1):50.
Score: 0.051
-
Yildirim Z, Delen F, Berron D, Baumeister H, Ziegler G, Sch?tze H, Glanz W, Dobisch L, Peters O, Freiesleben SD, Schneider LS, Priller J, Spruth EJ, Schneider A, Fliessbach K, Wiltfang J, Schott BH, Meiberth D, Buerger K, Janowitz D, Perneczky R, Rauchmann BS, Teipel S, Kilimann I, Laske C, Munk MH, Spottke A, Roy N, Heneka M, Brosseron F, Wagner M, Roeske S, Ramirez A, Ewers M, Dechent P, Hetzer S, Scheffler K, Kleineidam L, Wolfsgruber S, Yakupov R, Schmid M, Berger M, Gurvit H, Jessen F, Duzel E. Brain reserve contributes to distinguishing preclinical Alzheimer's stages 1 and 2. Alzheimers Res Ther. 2023 02 28; 15(1):43.
Score: 0.051
-
D?zel E, Ziegler G, Berron D, Maass A, Sch?tze H, Cardenas-Blanco A, Glanz W, Metzger C, Dobisch L, Reuter M, Spottke A, Brosseron F, Fliessbach K, Heneka MT, Laske C, Peters O, Priller J, Spruth EJ, Ramirez A, Speck O, Schneider A, Teipel S, Kilimann I, Jens W, Schott BH, Preis L, Gref D, Maier F, Munk MH, Roy N, Ballarini T, Yakupov R, Haynes JD, Dechent P, Scheffler K, Wagner M, Jessen F. Amyloid pathology but not APOE e4 status is permissive for tau-related hippocampal dysfunction. Brain. 2022 05 24; 145(4):1473-1485.
Score: 0.048
-
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, Aarsland D, Alcolea D, Altomare D, von Arnim C, Baiardi S, Baldeiras I, Barthel H, Bateman RJ, Van Berckel B, Binette AP, Blennow K, Boada M, Boecker H, Bottlaender M, den Braber A, Brooks DJ, Van Buchem MA, Camus V, Carill JM, Cerman J, Chen K, Ch?telat G, Chipi E, Cohen AD, Daniels A, Delarue M, Didic M, Drzezga A, Dubois B, Eckerstr?m M, Ekblad LL, Engelborghs S, Epelbaum S, Fagan AM, Fan Y, Fladby T, Fleisher AS, Van der Flier WM, F?rster S, Fortea J, Frederiksen KS, Freund-Levi Y, Frings L, Frisoni GB, Fr?hlich L, Gabryelewicz T, Gertz HJ, Gill KD, Gkatzima O, G?mez-Tortosa E, Grimmer T, Guedj E, Habeck CG, Hampel H, Handels R, Hansson O, Hausner L, Hellwig S, Heneka MT, Herukka SK, Hildebrandt H, Hodges J, Hort J, Huang CC, Iriondo AJ, Itoh Y, Ivanoiu A, Jagust WJ, Jessen F, Johannsen P, Johnson KA, Kandimalla R, Kapaki EN, Kern S, Kilander L, Klimkowicz-Mrowiec A, Klunk WE, Koglin N, Kornhuber J, Kramberger MG, Kuo HC, Van Laere K, Landau SM, Landeau B, Lee DY, de Leon M, Leyton CE, Lin KJ, Lle? A, L?wenmark M, Madsen K, Maier W, Marcusson J, Marqui? M, Martinez-Lage P, Maserejian N, Mattsson N, de Mendon?a A, Meyer PT, Miller BL, Minatani S, Mintun MA, Mok VCT, Molinuevo JL, Morbelli SD, Morris JC, Mroczko B, Na DL, Newberg A, Nobili F, Nordberg A, Olde Rikkert MGM, de Oliveira CR, Olivieri P, Orellana A, Paraskevas G, Parchi P, Pardini M, Parnetti L, Peters O, Poirier J, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Reiman EM, Rinne JO, Rodrigue KM, Rodr?guez-Rodriguez E, Roe CM, Rosa-Neto P, Rosen HJ, Rot U, Rowe CC, R?ther E, Ruiz A, Sabri O, Sakhardande J, S?nchez-Juan P, Sando SB, Santana I, Sarazin M, Scheltens P, Schr?der J, Selnes P, Seo SW, Silva D, Skoog I, Snyder PJ, Soininen H, Sollberger M, Sperling RA, Spiru L, Stern Y, Stomrud E, Takeda A, Teichmann M, Teunissen CE, Thompson LI, Tomassen J, Tsolaki M, Vandenberghe R, Verbeek MM, Verhey FRJ, Villemagne V, Villeneuve S, Vogelgsang J, Waldemar G, Wallin A, Wallin ?K, Wiltfang J, Wolk DA, Yen TC, Zboch M, Zetterberg H. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurol. 2022 03 01; 79(3):228-243.
Score: 0.047
-
Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lle? A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Ch?telat G, Ru?z A, Marqui? M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, S?nchez-Saudin?s MB, Ebenau J, Pocnet C, Eckerstr?m M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ?K, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L, Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ. Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimers Dement. 2022 10; 18(10):1832-1845.
Score: 0.047